APELLIS PHARMACEUTICALS INC. - COMMON STOCK

Apellis Announces Submission of New Drug Application to the FDA for Pegcetacoplan for Geographic Atrophy

01 6 2022 07:00:01 提供 Nasdaq GlobeNewswire

Apellis Announces Seven Abstracts in PNH to be Presented at the European Hematology Association Congress

12 5 2022 11:05:00 提供 Nasdaq GlobeNewswire

Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

06 5 2022 16:23:03 提供 Nasdaq GlobeNewswire

Apellis Pharmaceuticals to Present at the Bank of America Securities 2022 Healthcare Conference

05 5 2022 16:05:04 提供 Nasdaq GlobeNewswire

Apellis Pharmaceuticals Reports First Quarter 2022 Financial Results

04 5 2022 16:05:03 提供 Nasdaq GlobeNewswire

Apellis Announces Dr. Peter Hillmen, Renowned Hematologist and PNH Expert, to Join Company

03 5 2022 07:00:01 提供 Nasdaq GlobeNewswire

Apellis Announces Detailed 18-Month Results from Phase 3 DERBY and OAKS Studies of Pegcetacoplan for Geographic Atrophy (GA) at ARVO Annual Meeting

02 5 2022 15:30:00 提供 Nasdaq GlobeNewswire

Apellis Pharmaceuticals to Host Conference Call on May 4, 2022 to Discuss First Quarter 2022 Financial Results

26 4 2022 07:00:01 提供 Nasdaq GlobeNewswire

Apellis Announces Results from New Global Survey Conducted by The Harris Poll Revealing the Emotional Burden and Impact on Independence Caused by Geographic Atrophy (GA)

21 4 2022 07:00:02 提供 Nasdaq GlobeNewswire

Apellis Pharmaceuticals to Present at the 21st Annual Needham Virtual Healthcare Conference

04 4 2022 07:00:01 提供 Nasdaq GlobeNewswire

Apellis Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise of Option to Purchase Additional Shares

28 3 2022 16:01:00 提供 Nasdaq GlobeNewswire

Apellis Pharmaceuticals Announces Pricing of Public Offering of Common Stock

24 3 2022 07:00:01 提供 Nasdaq GlobeNewswire

Apellis Pharmaceuticals Announces Proposed Public Offering of Common Stock

23 3 2022 16:02:57 提供 Nasdaq GlobeNewswire

Apellis Announces Pegcetacoplan Showed Continuous and Clinically Meaningful Effects at Month 18 in Phase 3 DERBY and OAKS Studies for Geographic Atrophy (GA)

16 3 2022 07:00:00 提供 Nasdaq GlobeNewswire

Apellis Pharmaceuticals to Present at Upcoming Investor Conferences

02 3 2022 07:00:01 提供 Nasdaq GlobeNewswire

Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results

28 2 2022 16:05:01 提供 Nasdaq GlobeNewswire

Apellis Pharmaceuticals to Host Conference Call on February 28, 2022 to Discuss Fourth Quarter and Full Year 2021 Financial Results

22 2 2022 07:00:01 提供 Nasdaq GlobeNewswire

Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

06 1 2022 16:05:00 提供 Nasdaq GlobeNewswire

Apellis Pharmaceuticals to Present at the 40th Annual J.P. Morgan Healthcare Conference

03 1 2022 07:00:00 提供 Nasdaq GlobeNewswire

Apellis and Sobi Announce EU Approval of Aspaveli® (pegcetacoplan) for Treatment of PNH

15 12 2021 07:00:00 提供 Nasdaq GlobeNewswire